Clinical Efficacy of Ambroxol Combined with Budesonide Nebulized Inhalation in the Treatment of Neonatal Pneumonia
Objective To explore the clinical effect of ambroxol combined with budesonide nebulization inhalation in the treatment of neonatal pneumonia.Methods 102 newborns with pneumonia admitted to the hospital from January to December 2022 were selected as the research objects and randomly divided into an observation group and a control group using the odd even number method,with 51 cases in each group.The control group was treated with budesonide inhalation,while the observation group was treated with ambroxol combined with budesonide nebulization inhalation.Compare the lung function,inflammatory factor levels,and incidence of adverse reactions between two groups of children.Results After treatment,the peak expiratory flow rate(6.91±0.68)L/s and forced expiratory volume(3.61±0.62)L in the observation group were greater than(5.13±0.87)L/s,(2.26±0.43)L of the control group,with statistically significant differences between the groups(P<0.05).After treatment,the levels of tumor necrosis factor-α(16.34±5.85)pg/mL,interleukin-6(55.13±24.82)pg/mL,and hypersensitive C-reactive protein(15.23±5.14)mg/L in the observation group were lower than(26.25±6.41)pg/mL,(101.89±25.76)pg/mL,and(20.15±6.13)mg/L in the control group,and the differences between the groups were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion The clinical effect of ambroxol combined with budesonide nebulization inhalation in the treatment of neonatal pneumonia is significant,which can effectively improve the lung function of children,alleviate inflammatory reactions,and do not increase adverse reactions.
NETL
NSTL
万方数据
